The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Non-Tyrosine Kinase Inhibitors-Global Market Insights and Sales Trends 2025

Non-Tyrosine Kinase Inhibitors-Global Market Insights and Sales Trends 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1813389

No of Pages : 116

Ask Your Query
Synopsis
The global Non-Tyrosine Kinase Inhibitors market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Non-Tyrosine Kinase Inhibitors in various end use industries. The expanding demands from the Liver Cancer, Respiratory Cancer, Brain Cancer and Others, are propelling Non-Tyrosine Kinase Inhibitors market. mTOR Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the RAF/MEK Inhibitors segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Non-Tyrosine Kinase Inhibitors market, driven by demand from China, the second largest economy with some signs of stabilising, the Non-Tyrosine Kinase Inhibitors market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Non-Tyrosine Kinase Inhibitors, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Non-Tyrosine Kinase Inhibitors market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Non-Tyrosine Kinase Inhibitors market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Non-Tyrosine Kinase Inhibitors sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Non-Tyrosine Kinase Inhibitors covered in this report include Roche, Eli Lilly, Novartis, Array BioPharma, Nerviano Medical Sciences, Pfizer, Merck KGaA, Astex Pharmaceuticals and Cyclacel Pharmaceuticals, etc.
The global Non-Tyrosine Kinase Inhibitors market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche
Eli Lilly
Novartis
Array BioPharma
Nerviano Medical Sciences
Pfizer
Merck KGaA
Astex Pharmaceuticals
Cyclacel Pharmaceuticals
Daiichi Sankyo
Onconova Therapeutics
AstraZeneca
GlaxoSmithKline (GSK)
Carna Biosciences
Celgene Corporation
Eternity Bioscience
Jasco Pharmaceuticals
Global Non-Tyrosine Kinase Inhibitors market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Non-Tyrosine Kinase Inhibitors market, Segment by Type:
mTOR Inhibitors
RAF/MEK Inhibitors
CDK Inhibitors
Global Non-Tyrosine Kinase Inhibitors market, by Application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Non-Tyrosine Kinase Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Non-Tyrosine Kinase Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Non-Tyrosine Kinase Inhibitors Market Overview
1.1 Non-Tyrosine Kinase Inhibitors Product Overview
1.2 Non-Tyrosine Kinase Inhibitors Market Segment by Type
1.2.1 mTOR Inhibitors
1.2.2 RAF/MEK Inhibitors
1.2.3 CDK Inhibitors
1.3 Global Non-Tyrosine Kinase Inhibitors Market Size by Type
1.3.1 Global Non-Tyrosine Kinase Inhibitors Market Size Overview by Type (2018-2029)
1.3.2 Global Non-Tyrosine Kinase Inhibitors Historic Market Size Review by Type (2018-2023)
1.3.3 Global Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2018-2023)
1.4.2 Europe Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Breakdown by Type (2018-2023)
2 Global Non-Tyrosine Kinase Inhibitors Market Competition by Company
2.1 Global Top Players by Non-Tyrosine Kinase Inhibitors Sales (2018-2023)
2.2 Global Top Players by Non-Tyrosine Kinase Inhibitors Revenue (2018-2023)
2.3 Global Top Players by Non-Tyrosine Kinase Inhibitors Price (2018-2023)
2.4 Global Top Manufacturers Non-Tyrosine Kinase Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 Non-Tyrosine Kinase Inhibitors Market Competitive Situation and Trends
2.5.1 Non-Tyrosine Kinase Inhibitors Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Non-Tyrosine Kinase Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-Tyrosine Kinase Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into Non-Tyrosine Kinase Inhibitors Market
2.8 Key Manufacturers Non-Tyrosine Kinase Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Non-Tyrosine Kinase Inhibitors Status and Outlook by Region
3.1 Global Non-Tyrosine Kinase Inhibitors Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Non-Tyrosine Kinase Inhibitors Historic Market Size by Region
3.2.1 Global Non-Tyrosine Kinase Inhibitors Sales in Volume by Region (2018-2023)
3.2.2 Global Non-Tyrosine Kinase Inhibitors Sales in Value by Region (2018-2023)
3.2.3 Global Non-Tyrosine Kinase Inhibitors Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Region
3.3.1 Global Non-Tyrosine Kinase Inhibitors Sales in Volume by Region (2024-2029)
3.3.2 Global Non-Tyrosine Kinase Inhibitors Sales in Value by Region (2024-2029)
3.3.3 Global Non-Tyrosine Kinase Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Non-Tyrosine Kinase Inhibitors by Application
4.1 Non-Tyrosine Kinase Inhibitors Market Segment by Application
4.1.1 Liver Cancer
4.1.2 Respiratory Cancer
4.1.3 Brain Cancer
4.1.4 Others
4.2 Global Non-Tyrosine Kinase Inhibitors Market Size by Application
4.2.1 Global Non-Tyrosine Kinase Inhibitors Market Size Overview by Application (2018-2029)
4.2.2 Global Non-Tyrosine Kinase Inhibitors Historic Market Size Review by Application (2018-2023)
4.2.3 Global Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2018-2023)
4.3.2 Europe Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales Breakdown by Application (2018-2023)
5 North America Non-Tyrosine Kinase Inhibitors by Country
5.1 North America Non-Tyrosine Kinase Inhibitors Historic Market Size by Country
5.1.1 North America Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Non-Tyrosine Kinase Inhibitors Sales in Volume by Country (2018-2023)
5.1.3 North America Non-Tyrosine Kinase Inhibitors Sales in Value by Country (2018-2023)
5.2 North America Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Country
5.2.1 North America Non-Tyrosine Kinase Inhibitors Sales in Volume by Country (2024-2029)
5.2.2 North America Non-Tyrosine Kinase Inhibitors Sales in Value by Country (2024-2029)
6 Europe Non-Tyrosine Kinase Inhibitors by Country
6.1 Europe Non-Tyrosine Kinase Inhibitors Historic Market Size by Country
6.1.1 Europe Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Non-Tyrosine Kinase Inhibitors Sales in Volume by Country (2018-2023)
6.1.3 Europe Non-Tyrosine Kinase Inhibitors Sales in Value by Country (2018-2023)
6.2 Europe Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Country
6.2.1 Europe Non-Tyrosine Kinase Inhibitors Sales in Volume by Country (2024-2029)
6.2.2 Europe Non-Tyrosine Kinase Inhibitors Sales in Value by Country (2024-2029)
7 Asia-Pacific Non-Tyrosine Kinase Inhibitors by Region
7.1 Asia-Pacific Non-Tyrosine Kinase Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Non-Tyrosine Kinase Inhibitors Sales in Value by Region (2024-2029)
8 Latin America Non-Tyrosine Kinase Inhibitors by Country
8.1 Latin America Non-Tyrosine Kinase Inhibitors Historic Market Size by Country
8.1.1 Latin America Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Non-Tyrosine Kinase Inhibitors Sales in Volume by Country (2018-2023)
8.1.3 Latin America Non-Tyrosine Kinase Inhibitors Sales in Value by Country (2018-2023)
8.2 Latin America Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Country
8.2.1 Latin America Non-Tyrosine Kinase Inhibitors Sales in Volume by Country (2024-2029)
8.2.2 Latin America Non-Tyrosine Kinase Inhibitors Sales in Value by Country (2024-2029)
9 Middle East and Africa Non-Tyrosine Kinase Inhibitors by Country
9.1 Middle East and Africa Non-Tyrosine Kinase Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa Non-Tyrosine Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Non-Tyrosine Kinase Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Non-Tyrosine Kinase Inhibitors Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Roche
10.1.1 Roche Company Information
10.1.2 Roche Introduction and Business Overview
10.1.3 Roche Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Roche Non-Tyrosine Kinase Inhibitors Products Offered
10.1.5 Roche Recent Development
10.2 Eli Lilly
10.2.1 Eli Lilly Company Information
10.2.2 Eli Lilly Introduction and Business Overview
10.2.3 Eli Lilly Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Eli Lilly Non-Tyrosine Kinase Inhibitors Products Offered
10.2.5 Eli Lilly Recent Development
10.3 Novartis
10.3.1 Novartis Company Information
10.3.2 Novartis Introduction and Business Overview
10.3.3 Novartis Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Novartis Non-Tyrosine Kinase Inhibitors Products Offered
10.3.5 Novartis Recent Development
10.4 Array BioPharma
10.4.1 Array BioPharma Company Information
10.4.2 Array BioPharma Introduction and Business Overview
10.4.3 Array BioPharma Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Array BioPharma Non-Tyrosine Kinase Inhibitors Products Offered
10.4.5 Array BioPharma Recent Development
10.5 Nerviano Medical Sciences
10.5.1 Nerviano Medical Sciences Company Information
10.5.2 Nerviano Medical Sciences Introduction and Business Overview
10.5.3 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Nerviano Medical Sciences Non-Tyrosine Kinase Inhibitors Products Offered
10.5.5 Nerviano Medical Sciences Recent Development
10.6 Pfizer
10.6.1 Pfizer Company Information
10.6.2 Pfizer Introduction and Business Overview
10.6.3 Pfizer Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Pfizer Non-Tyrosine Kinase Inhibitors Products Offered
10.6.5 Pfizer Recent Development
10.7 Merck KGaA
10.7.1 Merck KGaA Company Information
10.7.2 Merck KGaA Introduction and Business Overview
10.7.3 Merck KGaA Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Merck KGaA Non-Tyrosine Kinase Inhibitors Products Offered
10.7.5 Merck KGaA Recent Development
10.8 Astex Pharmaceuticals
10.8.1 Astex Pharmaceuticals Company Information
10.8.2 Astex Pharmaceuticals Introduction and Business Overview
10.8.3 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Astex Pharmaceuticals Non-Tyrosine Kinase Inhibitors Products Offered
10.8.5 Astex Pharmaceuticals Recent Development
10.9 Cyclacel Pharmaceuticals
10.9.1 Cyclacel Pharmaceuticals Company Information
10.9.2 Cyclacel Pharmaceuticals Introduction and Business Overview
10.9.3 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Cyclacel Pharmaceuticals Non-Tyrosine Kinase Inhibitors Products Offered
10.9.5 Cyclacel Pharmaceuticals Recent Development
10.10 Daiichi Sankyo
10.10.1 Daiichi Sankyo Company Information
10.10.2 Daiichi Sankyo Introduction and Business Overview
10.10.3 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Daiichi Sankyo Non-Tyrosine Kinase Inhibitors Products Offered
10.10.5 Daiichi Sankyo Recent Development
10.11 Onconova Therapeutics
10.11.1 Onconova Therapeutics Company Information
10.11.2 Onconova Therapeutics Introduction and Business Overview
10.11.3 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Onconova Therapeutics Non-Tyrosine Kinase Inhibitors Products Offered
10.11.5 Onconova Therapeutics Recent Development
10.12 AstraZeneca
10.12.1 AstraZeneca Company Information
10.12.2 AstraZeneca Introduction and Business Overview
10.12.3 AstraZeneca Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.12.4 AstraZeneca Non-Tyrosine Kinase Inhibitors Products Offered
10.12.5 AstraZeneca Recent Development
10.13 GlaxoSmithKline (GSK)
10.13.1 GlaxoSmithKline (GSK) Company Information
10.13.2 GlaxoSmithKline (GSK) Introduction and Business Overview
10.13.3 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.13.4 GlaxoSmithKline (GSK) Non-Tyrosine Kinase Inhibitors Products Offered
10.13.5 GlaxoSmithKline (GSK) Recent Development
10.14 Carna Biosciences
10.14.1 Carna Biosciences Company Information
10.14.2 Carna Biosciences Introduction and Business Overview
10.14.3 Carna Biosciences Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Carna Biosciences Non-Tyrosine Kinase Inhibitors Products Offered
10.14.5 Carna Biosciences Recent Development
10.15 Celgene Corporation
10.15.1 Celgene Corporation Company Information
10.15.2 Celgene Corporation Introduction and Business Overview
10.15.3 Celgene Corporation Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Celgene Corporation Non-Tyrosine Kinase Inhibitors Products Offered
10.15.5 Celgene Corporation Recent Development
10.16 Eternity Bioscience
10.16.1 Eternity Bioscience Company Information
10.16.2 Eternity Bioscience Introduction and Business Overview
10.16.3 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Eternity Bioscience Non-Tyrosine Kinase Inhibitors Products Offered
10.16.5 Eternity Bioscience Recent Development
10.17 Jasco Pharmaceuticals
10.17.1 Jasco Pharmaceuticals Company Information
10.17.2 Jasco Pharmaceuticals Introduction and Business Overview
10.17.3 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Sales, Revenue and Gross Margin (2018-2023)
10.17.4 Jasco Pharmaceuticals Non-Tyrosine Kinase Inhibitors Products Offered
10.17.5 Jasco Pharmaceuticals Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Non-Tyrosine Kinase Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Non-Tyrosine Kinase Inhibitors Industrial Chain Analysis
11.4 Non-Tyrosine Kinase Inhibitors Market Dynamics
11.4.1 Non-Tyrosine Kinase Inhibitors Industry Trends
11.4.2 Non-Tyrosine Kinase Inhibitors Market Drivers
11.4.3 Non-Tyrosine Kinase Inhibitors Market Challenges
11.4.4 Non-Tyrosine Kinase Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Non-Tyrosine Kinase Inhibitors Distributors
12.3 Non-Tyrosine Kinase Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock